Shrinking Covid vaccine sales has Moderna course-correcting

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

There’s potential that a stem cell infusion from kidney donors might help prevent organ rejection — allowing patients to perhaps wean from immunosuppressive drugs. We see the Senate is getting serious about PBMs, and have a neat podcast, as always. Have a good weekend!

The need-to-know this morning
• The 9.1-million share initial public offering for Lexeo Therapeutics was priced at $11 per share — below the requested range of $13-15 per share.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In